Emma Andrus, Associate Editor

Dermatology Times asked our readers to share what conferences they are looking forward to in the fourth quarter of 2024.

Dermatology Times is looking back on the top stories in dermatology from the month of October.

Dermatology Times is recapping our top expert interviews from the month of October.

Catch up on coverage from the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

In a Dermatology Times Case-Based Roundtable event, Pearl E. Grimes, MD, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib.

Manson Brown discusses Allergan Aesthetics' Science of Aging program, highlighting its role in shifting from anti-aging to pro-longevity in aesthetic medicine.

Belleson addresses one of the NEA's Eczema Awareness Month weekly themes, “The eczema community is here to inspire you.”

Discover top innovations, insights, and clinical pearls from Fall Clinical in Las Vegas, where dermatology’s biggest breakthroughs took center stage.

Deucravacitinib demonstrated significant efficacy and safety in treating moderate to severe scalp psoriasis, as shown in the PSORIATYK SCALP trial presented at Fall Clinical.

At Fall Clinical 2024, Graber spotlighted precise acne-targeting lasers, new combination creams, and a promising rosacea pill awaiting FDA approval.

Song shared top clinical tips at Fall Clinical, covering alopecia areata, refractory dermatoses, and novel non-steroidal topicals.

The recent meta-analysis revealed comparable efficacy in treating acne vulgaris and was presented at Fall Clinical 2024.

Catch up on coverage from the third day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

The phase 3b study shows Ebglyss reduced eczema severity and itch in challenging areas, with 60% of prior dupilumab patients meeting key improvement by week 24.

Adbry achieved EASI-75 in 92.9% and IGA 0/1 in 66.7% of AD patients, with a strong safety profile.

Sun Pharma presented long-term data on Leqselvi 8 mg tablets, showing significant scalp hair regrowth in severe alopecia areata patients.

Catch up on coverage from the second day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

Shahriari highlighted advanced dermatology treatments, clinical trial inclusivity, and key care strategies for complex skin conditions at Fall Clinical 2024.

Phase 3b study showed promise in clearing moderate PsO in sensitive areas for patients unresponsive to topical treatments.

Clinicians presented a panel-style session at Fall Clinical, touching on the drawbacks of topical steroid use and alternatives in AD patients.

Among the many sessions to be held at the Fall Clinical Dermatology Conference in Las Vegas, Nevada, several Dermatology Times Editorial Advisory Board members are preparing to share their knowledge and insights.

The conference aimed at providing dermatology clinicians with the latest in the specialty begins today in Las Vegas, Nevada.

We want to know: Will you be attending the conference in Las Vegas later this week?

In a Dermatology Times Case-Based Roundtable event, Ted Lain, MD, MBA, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib.

Shi addresses one of the NEA's Eczema Awareness Month weekly themes, "Creative ways to manage your eczema."

Lio addresses one of the NEA's Eczema Awareness Month weekly themes, "What is eczema?"

Historically, research and clinical practice often have overlooked the distinct manifestations and treatment needs of patients with skin of color who have psoriasis.

This represents the second approval of Zoryve outside the US.

Forlenza addresses one of the NEA's Eczema Awareness Month weekly themes, "Tools for living your most ecz-pressive life with eczema."

The study represents the first to evaluate health care resource utilization among individuals with PN in England.